New data from Pitt County Schools shows 81 students in the district are not up to date on their immunizations.

Zanzalintinib and atezolizumab improved overall survival in metastatic colorectal cancer compared to regorafenib, with a median OS of 10.9 vs 9.4 months. The combination showed progression-free ...

Discover ITT Inc.'s growth in revenue and profits, current valuation, and future outlook. Click for why a Hold rating is ...

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

ITT Tech announced Tuesday morning that it’s closing its for-profit technical schools nationwide, which includes more than 130 campuses, two of which are in Charlotte.

In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Roche (RHHBF) unit Genentech posts encouraging late-stage trial data for its breast cancer drug giredestrant noting up to 62% ...

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard- ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

Adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improved PFS in patients with platinum-resistant, recurrent ovarian cancer in a phase 3 trial.